Who is sponsoring NCT03456947?

NCT03456947 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT03456947?

Interventions in NCT03456947: Pregabalin.

What condition does NCT03456947 study?

NCT03456947 studies Effect of Laryngoscopy and Tracheal Intubation.

Is NCT03456947 still recruiting?

NCT03456947 is currently completed. Last updated 9 March 2018.

Last reviewed 2018-03-09 · How we verify

NCT03456947

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pregabalin Stabilize Cardiovascular Response to Intubation

Completed Phase 4 Last updated 9 March 2018

What this trial tests

Phase 4 trial testing Pregabalin in Effect of Laryngoscopy and Tracheal Intubation in 90 participants. Completed in 30 June 2017.

Timeline

1 January 2017

Primary endpoint
30 June 2017

30 June 2017

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	90
Start date	1 January 2017
Primary completion	30 June 2017
Estimated completion	30 June 2017

Drugs / interventions tested

Pregabalin (Pregabalin) — full drug profile →

Conditions studied

Effect of Laryngoscopy and Tracheal Intubation — all drugs for Effect of Laryngoscopy and Tracheal Intubation →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 60, any sex, with Effect of Laryngoscopy and Tracheal Intubation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate whether Pregabalin is safe and effective in stabilizing cardiovascular response to laryngoscopy and tracheal intubation of patients under general anesthesia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Preoperative Low-dose and High-dose Pregabalin and Cardiovascular Response to Endotracheal Intubation: A Prospective, Randomized, Single-blind, Controlled Study in China.
Chen W, Huang H, Yang C, Hu X, et al · · 2019 · cited 5× · PMID 30553555 · DOI 10.1016/j.clinthera.2018.11.006

Verify or expand the search:

Other trials of Pregabalin

Trials testing the same drug.

NCT07288528 — A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Ref · Phase 4 · not yet recruiting
NCT07421427 — Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome · NA · recruiting
NCT07275762 — Y-4 to Treat the Postherpetic Neuralgia · Phase 2 · recruiting
NCT07208357 — The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia · NA · recruiting
NCT07196657 — The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia · NA · recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03456947 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 9 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03456947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing